vs
Guardant Health, Inc.（GH）与世纪互联（VNET）财务数据对比。点击上方公司名可切换其他公司
世纪互联的季度营收约是Guardant Health, Inc.的1.3倍（$362.7M vs $281.3M），世纪互联净利率更高（-10.7% vs -45.7%，领先35.0%），Guardant Health, Inc.自由现金流更多（$-54.2M vs $-193.1M），过去两年Guardant Health, Inc.的营收复合增速更高（29.2% vs 17.4%）
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
VNET Group即世纪互联，是中国领先的第三方中立数据中心服务商，提供机柜托管、云基础设施、混合云部署及网络管理等解决方案，服务覆盖科技、金融、零售等多领域企业客户，为企业数字化运营提供稳定的算力与网络支撑。
GH vs VNET — 直观对比
营收规模更大
VNET
是对方的1.3倍
$281.3M
净利率更高
VNET
高出35.0%
-45.7%
自由现金流更多
GH
多$138.9M
$-193.1M
两年增速更快
GH
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $281.3M | $362.7M |
| 净利润 | $-128.5M | $-38.7M |
| 毛利率 | 64.6% | 20.9% |
| 营业利润率 | -43.0% | 0.5% |
| 净利率 | -45.7% | -10.7% |
| 营收同比 | 39.4% | — |
| 净利润同比 | -15.8% | — |
| 每股收益（稀释后） | $-1.01 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GHVNET
| Q4 25 | $281.3M | — | ||
| Q3 25 | $265.2M | $362.7M | ||
| Q2 25 | $232.1M | — | ||
| Q1 25 | $203.5M | $309.5M | ||
| Q4 24 | $201.8M | — | ||
| Q3 24 | $191.5M | $302.2M | ||
| Q2 24 | $177.2M | $274.4M | ||
| Q1 24 | $168.5M | $262.9M |
净利润GHVNET
| Q4 25 | $-128.5M | — | ||
| Q3 25 | $-92.7M | $-38.7M | ||
| Q2 25 | $-99.9M | — | ||
| Q1 25 | $-95.2M | $-2.4M | ||
| Q4 24 | $-111.0M | — | ||
| Q3 24 | $-107.8M | $-2.1M | ||
| Q2 24 | $-102.6M | $-1.1M | ||
| Q1 24 | $-115.0M | $-22.0M |
毛利率GHVNET
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | 20.9% | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | 25.2% | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | 23.2% | ||
| Q2 24 | 59.1% | 21.3% | ||
| Q1 24 | 61.2% | 21.6% |
营业利润率GHVNET
| Q4 25 | -43.0% | — | ||
| Q3 25 | -37.3% | 0.5% | ||
| Q2 25 | -45.9% | — | ||
| Q1 25 | -54.6% | 0.1% | ||
| Q4 24 | -62.4% | — | ||
| Q3 24 | -61.3% | 24.5% | ||
| Q2 24 | -56.8% | 0.2% | ||
| Q1 24 | -59.2% | 0.2% |
净利率GHVNET
| Q4 25 | -45.7% | — | ||
| Q3 25 | -35.0% | -10.7% | ||
| Q2 25 | -43.0% | — | ||
| Q1 25 | -46.8% | -0.8% | ||
| Q4 24 | -55.0% | — | ||
| Q3 24 | -56.3% | -0.7% | ||
| Q2 24 | -57.9% | -0.4% | ||
| Q1 24 | -68.2% | -8.4% |
每股收益（稀释后）GHVNET
| Q4 25 | $-1.01 | — | ||
| Q3 25 | $-0.74 | — | ||
| Q2 25 | $-0.80 | — | ||
| Q1 25 | $-0.77 | — | ||
| Q4 24 | $-0.90 | — | ||
| Q3 24 | $-0.88 | — | ||
| Q2 24 | $-0.84 | — | ||
| Q1 24 | $-0.94 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $378.2M | $492.1M |
| 总债务越低越好 | $1.5B | — |
| 股东权益账面价值 | $-99.3M | $890.8M |
| 总资产 | $2.0B | $6.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GHVNET
| Q4 25 | $378.2M | — | ||
| Q3 25 | $580.0M | $492.1M | ||
| Q2 25 | $629.1M | — | ||
| Q1 25 | $698.6M | $544.3M | ||
| Q4 24 | $525.5M | — | ||
| Q3 24 | $585.0M | $219.5M | ||
| Q2 24 | $933.7M | $247.2M | ||
| Q1 24 | $1.0B | $246.9M |
总债务GHVNET
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益GHVNET
| Q4 25 | $-99.3M | — | ||
| Q3 25 | $-354.5M | $890.8M | ||
| Q2 25 | $-305.5M | — | ||
| Q1 25 | $-250.8M | $927.8M | ||
| Q4 24 | $-139.6M | — | ||
| Q3 24 | $-60.1M | $902.9M | ||
| Q2 24 | $-1.6M | $900.6M | ||
| Q1 24 | $68.3M | $895.1M |
总资产GHVNET
| Q4 25 | $2.0B | — | ||
| Q3 25 | $1.3B | $6.1B | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $1.3B | $5.4B | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.5B | $4.3B | ||
| Q2 24 | $1.6B | $4.0B | ||
| Q1 24 | $1.7B | $3.9B |
负债/权益比GHVNET
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.28× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-26.4M | $113.8M |
| 自由现金流经营现金流 - 资本支出 | $-54.2M | $-193.1M |
| 自由现金流率自由现金流/营收 | -19.3% | -53.2% |
| 资本支出强度资本支出/营收 | 9.9% | 84.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-233.1M | $-589.7M |
8季度趋势，按日历期对齐
经营现金流GHVNET
| Q4 25 | $-26.4M | — | ||
| Q3 25 | $-35.4M | $113.8M | ||
| Q2 25 | $-60.3M | — | ||
| Q1 25 | $-62.7M | $27.0M | ||
| Q4 24 | $-64.5M | — | ||
| Q3 24 | $-51.1M | $108.3M | ||
| Q2 24 | $-94.0M | $55.8M | ||
| Q1 24 | $-30.3M | $37.1M |
自由现金流GHVNET
| Q4 25 | $-54.2M | — | ||
| Q3 25 | $-45.8M | $-193.1M | ||
| Q2 25 | $-65.9M | — | ||
| Q1 25 | $-67.1M | $-220.0M | ||
| Q4 24 | $-83.4M | — | ||
| Q3 24 | $-55.3M | $-95.0M | ||
| Q2 24 | $-99.1M | $-81.6M | ||
| Q1 24 | $-37.2M | $-102.2M |
自由现金流率GHVNET
| Q4 25 | -19.3% | — | ||
| Q3 25 | -17.3% | -53.2% | ||
| Q2 25 | -28.4% | — | ||
| Q1 25 | -33.0% | -71.1% | ||
| Q4 24 | -41.3% | — | ||
| Q3 24 | -28.9% | -31.4% | ||
| Q2 24 | -55.9% | -29.8% | ||
| Q1 24 | -22.1% | -38.9% |
资本支出强度GHVNET
| Q4 25 | 9.9% | — | ||
| Q3 25 | 3.9% | 84.6% | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | 2.2% | 79.8% | ||
| Q4 24 | 9.4% | — | ||
| Q3 24 | 2.2% | 67.3% | ||
| Q2 24 | 2.9% | 50.1% | ||
| Q1 24 | 4.1% | 53.0% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
VNET
暂无分部数据
